Ozempic and Wegovy oral weight-loss pills now available for Amazon same-day delivery
Novo Nordisk has made its oral versions of the popular weight-loss drugs, Ozempic and Wegovy, available for same-day delivery on Amazon.
CEO Mike Doustdar shared on “The Claman Countdown” that the once-daily pill versions of the treatments have been a huge success.
“It’s an exciting time for patients to have quick access to these products,” he mentioned on FOX Business.
“I think it’s great that people can now choose between the Ozempic injection and the new Ozempic pill.”
The Ozempic pill was launched recently, following the introduction of an oral version of Wegovy in January, which has seen impressive sales of over $350 million in the first quarter.
“This has been the most successful product launch in the past decade. I’m thrilled with the results,” Doustdar stated.
“Since the launch, over a million patients have tried it in just 16 weeks.”
Ozempic is for Type 2 Diabetes patients, while Wegovy is used to treat obesity. Both were initially in injectable form but now come in convenient once-daily pill versions.
“I believe Wegovy’s pill will be the flagship product, but the Ozempic pill will also have its place due to its iconic brand name,” Doustdar added.
Novo Nordisk was among the first companies to collaborate with the Trump administration to reduce prescription drug costs, emphasizing the importance of fair access.
“Lower prices have led to more patients and volume for us. While it may hurt our business in the short term, it’s the right move in the long run,” the CEO explained.
Aside from weight loss, Doustdar highlighted the drugs’ positive effects on cardiovascular, kidney, and liver health, including the potential to reverse scarring in fatty liver disease patients.
He also mentioned a new drug treatment in development that shows promise in treating liver disease and potentially reducing the need for liver transplants.
“We are still in the process of clinical development and approval, but if the early data is any indication, I’m very optimistic,” Doustdar concluded.
